# Irofulven in Treating Patients With Metastatic Breast Cancer

> **NCT00003796** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** irofulven

## Key facts

- **NCT ID:** NCT00003796
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-05
- **Primary completion:** 2003-12
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003796, "Irofulven in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*